date: 2022-06-10T04:37:55Z
pdf:PDFVersion: 1.4
pdf:docinfo:title: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
xmp:CreatorTool: Adobe InDesign 15.0 (Windows)
access_permission:can_print_degraded: true
subject: Molecular Cancer, https://doi.org/10.1186/s12943-022-01583-z
pdfa:PDFVersion: A-2b
xmpMM:History:Action: converted
language: en-US
dc:format: application/pdf; version=1.4
pdf:docinfo:custom:robots: noindex
pdf:docinfo:creator_tool: Adobe InDesign 15.0 (Windows)
access_permission:fill_in_form: true
xmpMM:History:When: 2022-06-09T12:05:22Z
pdf:encrypted: false
dc:title: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
modified: 2022-06-10T04:37:55Z
cp:subject: Molecular Cancer, https://doi.org/10.1186/s12943-022-01583-z
xmpMM:History:SoftwareAgent: pdfToolbox
pdf:docinfo:custom:CrossMarkDomains[1]: springer.com
robots: noindex
pdf:docinfo:subject: Molecular Cancer, https://doi.org/10.1186/s12943-022-01583-z
xmpMM:History:InstanceID: uuid:c7e10cb6-bd4c-4fcf-9930-35843768bf4e
pdf:docinfo:creator:  Mareike Berlak
meta:author:  ElizabethTucker
trapped: False
meta:creation-date: 2022-06-08T18:56:13Z
pdf:docinfo:custom:CrossmarkMajorVersionDate: 2010-04-23
created: 2022-06-08T18:56:13Z
access_permission:extract_for_accessibility: true
Creation-Date: 2022-06-08T18:56:13Z
pdfaid:part: 2
pdf:docinfo:custom:CrossMarkDomains[2]: springerlink.com
pdf:docinfo:custom:doi: 10.1186/s12943-022-01583-z
pdf:docinfo:custom:CrossmarkDomainExclusive: true
Author:  ElizabethTucker
producer: Adobe PDF Library 15.0; modified using iText® 5.3.5 ©2000-2012 1T3XT BVBA (SPRINGER SBM; licensed version)
CrossmarkDomainExclusive: true
pdf:docinfo:producer: Adobe PDF Library 15.0; modified using iText® 5.3.5 ©2000-2012 1T3XT BVBA (SPRINGER SBM; licensed version)
doi: 10.1186/s12943-022-01583-z
pdf:unmappedUnicodeCharsPerPage: 0
dc:description: Molecular Cancer, https://doi.org/10.1186/s12943-022-01583-z
Keywords: Neuroblastoma;CRISPR screening;ALK;Resistance;NF1;NRAS;Trametinib;Lorlatinib;Ceritinib;Collateral sensitivity
access_permission:modify_annotations: true
dc:creator:  ElizabethTucker
description: Molecular Cancer, https://doi.org/10.1186/s12943-022-01583-z
dcterms:created: 2022-06-08T18:56:13Z
Last-Modified: 2022-06-10T04:37:55Z
dcterms:modified: 2022-06-10T04:37:55Z
title: Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
xmpMM:DocumentID: uuid:c7e10cb6-bd4c-4fcf-9930-35843768bf4e
Last-Save-Date: 2022-06-10T04:37:55Z
CrossMarkDomains[1]: springer.com
pdf:docinfo:keywords: Neuroblastoma;CRISPR screening;ALK;Resistance;NF1;NRAS;Trametinib;Lorlatinib;Ceritinib;Collateral sensitivity
pdf:docinfo:modified: 2022-06-10T04:37:55Z
meta:save-date: 2022-06-10T04:37:55Z
Content-Type: application/pdf
X-Parsed-By: org.apache.tika.parser.DefaultParser
creator:  ElizabethTucker
pdfaid:conformance: B
dc:language: en-US
dc:subject: Neuroblastoma;CRISPR screening;ALK;Resistance;NF1;NRAS;Trametinib;Lorlatinib;Ceritinib;Collateral sensitivity
access_permission:assemble_document: true
xmpTPg:NPages: 19
pdf:charsPerPage: 3976
access_permission:extract_content: true
access_permission:can_print: true
pdf:docinfo:trapped: False
CrossMarkDomains[2]: springerlink.com
meta:keyword: Neuroblastoma;CRISPR screening;ALK;Resistance;NF1;NRAS;Trametinib;Lorlatinib;Ceritinib;Collateral sensitivity
access_permission:can_modify: true
pdf:docinfo:created: 2022-06-08T18:56:13Z
CrossmarkMajorVersionDate: 2010-04-23